Phathom Pharmaceuticals, Inc. Logo

Phathom Pharmaceuticals, Inc.

Develops and commercializes treatments for acid-related gastrointestinal diseases.

PHAT | US

Overview

Corporate Details

ISIN(s):
US71722W1071
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE,, 7932 FLORHAM PARK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for acid-related gastrointestinal (GI) diseases. The company's mission is to transform the treatment landscape and improve the lives of patients with these conditions. Its primary commercial product is VOQUEZNA® (vonoprazan), a prescription medicine for adults used to treat Erosive Esophagitis and Gastroesophageal Reflux Disease (GERD). Phathom advances late-stage clinical programs to address unmet needs in gastroenterology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:05
Regulatory News Service
8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
English 58.2 KB

Automate Your Workflow. Get a real-time feed of all Phathom Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Phathom Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Phathom Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN

Talk to a Data Expert

Have a question? We'll get back to you promptly.